Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lunai Bioworks Inc. (LNAI:NASDAQ), powered by AI.
Lunai Bioworks Inc. is currently trading at $0.41. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lunai Bioworks Inc. on Alpha Lenz.
Lunai Bioworks Inc.'s P/E ratio is -0.0.
“Lunai Bioworks Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 833.8%.”
Ask for details →Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
“Lunai Bioworks Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 833.8%.”
Ask for details →Lunai Bioworks Inc. (ticker: LNAI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 29 employees. Market cap is $7M.
The current price is $0.414 with a P/E ratio of -0.04x and P/B of -0.32x.
ROE is 833.76%.